Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsAntonio Omuro, MD
Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Professor Adjunct
Biography
Dr. Omuro is a Professor Adjunct in the department of Neurology at the Yale School of Medicine.
He is the former chief of the Division of Neuro-Oncology and Director of the Yale Brain Tumor Center. He is a graduate and former faculty of the Neuro-Oncology program at Memorial Sloan Kettering Cancer Center in New York. Dr. Omuro is an internationally renowned leader in clinical care and research in the field of brain tumors, having led pivotal research projects and clinical trials to advance the treatment of these difficult cancers.
Dr. Omuro is currently the chair of the Department of Neurology and Neurological Sciences at Stanford University.
Last Updated on July 15, 2024.
Departments & Organizations
Education & Training
- Fellow
- Memorial Sloan Kettering Cancer Center (2004)
- MD
- Sao Paulo School of Medicine (1995)
Research
Copy Link
Overview
Dr. Omuro is an international leader in the research of brain tumors, having led pivotal research programs and clinical trials to advance the treatment of these difficult cancers.
Medical Research Interests
Central Nervous System Neoplasms; Clinical Trial; Glioblastoma; Meningeal Neoplasms
ORCID
0000-0003-4299-3664
Research at a Glance
Yale Co-Authors
Frequent collaborators of Antonio Omuro's published research.
Publications Timeline
A big-picture view of Antonio Omuro's research output by year.
Research Interests
Research topics Antonio Omuro is interested in exploring.
Sanjay Aneja, MD
Veronica Chiang, MD, FAANS
MingDe Lin, PhD
Alexandria Brackett, MLIS, AHIP, MA
Lawrence Staib, PhD
Sacit Bulent Omay, MD, FAANS
159Publications
25,106Citations
Central Nervous System Neoplasms
Glioblastoma
Meningeal Neoplasms
Publications
2026
Chapter 41 Chemotherapy for primary central nervous system lymphoma
Therkelsen K, Omuro A. Chapter 41 Chemotherapy for primary central nervous system lymphoma. 2026, 675-692. DOI: 10.1016/b978-0-443-27356-8.00028-0.BooksConceptsCentral nervous systemChemotherapy regimensHigh-dose methotrexate-based chemotherapyChimeric antigen receptor T cellsPrimary central nervous system lymphomaCentral nervous system lymphomaPrimary central nervous systemMethotrexate-based chemotherapyMethotrexate-based regimensMyeloablative chemotherapy regimensImmune checkpoint inhibitorsNervous system lymphomaStem-cell transplantationImmunomodulatory imide drugsCheckpoint inhibitorsSystem lymphomaMaintenance therapyRecurrent diseaseT cellsRandomized studyPoor outcomeRegimensBTK inhibitorsClinical trialsPatient population
2025
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas
Schiff D, Ye X, Li J, Ellingson B, Wen P, Walbert T, Campian J, Nabors L, Ozer B, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra R. Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. Neuro-Oncology 2025, 28: 485-494. PMID: 41099363, PMCID: PMC12979031, DOI: 10.1093/neuonc/noaf246.Peer-Reviewed Original ResearchCitationsAltmetricConceptsWindow-of-opportunity studyProgression-free survivalIDH mutant gliomasMutant gliomasPARP inhibitorsIntratumoral pharmacokineticsMedian progression-free survivalProlonged progression-free survivalArm B patientsCumulative hematologic toxicityLow-dose temozolomidePhase II doseActivity of PARP inhibitorsLong-term tolerancePharmacologically active concentrationsNon-enhancing tumorDaily temozolomideII doseMetronomic temozolomideRANO criteriaHematologic toxicityRadiographic responseRecurrent gliomaPartial responseArm AMulticenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma
Omuro A, DeAngelis L, Polley M, Correa D, Wefel J, Bovi J, Rosenblum M, Corn B, Aneja S, Grommes C, Peereboom D, Lallana E, Werner-Wasik M, Rogers C, Iwamoto F, Yu H, Donnelly E, Struve T, Won M, Mehta M. Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro-Oncology 2025, 28: 371-382. PMID: 41189315, PMCID: PMC12904153, DOI: 10.1093/neuonc/noaf221.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPrimary central nervous system lymphomaProgression-free survivalMulticenter randomized phase II studyWhole-brain radiotherapyOverall survivalIntent-to-treatHazard ratioDose of whole-brain radiotherapyRisk of severe neurotoxicityCentral nervous system lymphomaLow radiotherapy dosesPrimary CNS lymphomaNervous system lymphomaSingle-arm studyDisease controlCNS lymphomaRadiotherapy doseSystem lymphomaPrimary endpointMedian ageChemoRTLow-doseSevere neurotoxicityFollow-upResponse rate
2024
Advances in Primary Central Nervous System Lymphoma
Therkelsen K, Omuro A. Advances in Primary Central Nervous System Lymphoma. Current Neurology And Neuroscience Reports 2024, 25: 5. PMID: 39585484, DOI: 10.1007/s11910-024-01389-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsOlder patientsPrimary central nervous system lymphomaCAR-T cell treatmentCSF cell-free DNACentral nervous system lymphomaPrimary CNS lymphomaPathway-targeted therapiesNervous system lymphomaLow-dose radiationCell-free DNALong-term outcomesGoal of treatmentDevelopment of therapiesCNS lymphomaPCNSL patientsConsolidation therapyCAR-TSystem lymphomaProspective trialsInitial managementTreatment optionsSalvage optionClinical trialsPatientsNeurocognitive outcomesRadiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach
Wang D, Geng H, Gondi V, Lee N, Tsien C, Xia P, Chenevert T, Michalski J, Gilbert M, Le Q, Omuro A, Men K, Aldape K, Cao Y, Srinivasan A, Barani I, Sachdev S, Huang J, Choi S, Shi W, Battiste J, Wardak Z, Chan M, Mehta M, Xiao Y. Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach. Cancers 2024, 16: 2007. PMID: 38893130, PMCID: PMC11171017, DOI: 10.3390/cancers16112007.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIntensity-modulated proton therapyPlan quality assuranceOrgan-at-riskRT planningQuality of radiation therapyClinical trialsIMPT plansKBP modelPlan QAPhoton plansRadiation therapyPhoton modelKBP plansTarget coveragePlan qualityProton therapyNasopharyngeal carcinomaMulti-institutional clinical trialsNRG Oncology trialsProton modelOutcomes of clinical trialsMulti-center clinical trialPhoton RTQuality assuranceHead/neck cancerEnhancing clinical decision-making: An externally validated machine learning model for predicting isocitrate dehydrogenase mutation in gliomas using radiomics from presurgical magnetic resonance imaging
Lost J, Ashraf N, Jekel L, von Reppert M, Tillmanns N, Willms K, Merkaj S, Petersen G, Avesta A, Ramakrishnan D, Omuro A, Nabavizadeh A, Bakas S, Bousabarah K, Lin M, Aneja S, Sabel M, Aboian M. Enhancing clinical decision-making: An externally validated machine learning model for predicting isocitrate dehydrogenase mutation in gliomas using radiomics from presurgical magnetic resonance imaging. Neuro-Oncology Advances 2024, 6: vdae157. PMID: 39659829, PMCID: PMC11630777, DOI: 10.1093/noajnl/vdae157.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIsocitrate dehydrogenase mutation statusArea under the curveMagnetic resonance imagingMutation statusML modelsMachine learningSemi-automated tumour segmentationsPre-surgical magnetic resonance imagingCare of glioma patientsMachine learning modelsClinical care of glioma patientsIsocitrate dehydrogenase statusAnnotated datasetsFeature extractionPrediction taskMulti-institutional dataModel trainingIDH mutationsPredicting IDH mutationLearning modelsRetrospective studyHeterogeneous datasetsTumor segmentationGlioma patientsBrain tumors
2023
Imaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original ResearchThe Yale Glioma Dataset: Developing An Open Access, Annotated MRI Database
Sala M, Lost J, Tillmanns N, Merkaj S, von Reppert M, Ramakrishnan D, Bousabarah K, Huttner A, Aneja S, Avesta A, Omuro A, Aboian M. The Yale Glioma Dataset: Developing An Open Access, Annotated MRI Database. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/4511.Peer-Reviewed Original ResearchComparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging
Joel M, Avesta A, Yang D, Zhou J, Omuro A, Herbst R, Krumholz H, Aneja S. Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging. Cancers 2023, 15: 1548. PMID: 36900339, PMCID: PMC10000732, DOI: 10.3390/cancers15051548.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAdversarial imagesDeep learning modelsDL modelsDetection modelLearning modelConvolutional neural networkDetection schemeAdversarial detectionDefense techniquesMachine learningMedical imagesAdversarial perturbationsInput imageAdversarial trainingNeural networkArt performanceMagnetic resonance imagingGradient descentPixel valuesHigh accuracyImagesBrain magnetic resonance imagingAbsence of malignancyClassificationSchemeTop advances of the year: Neuro‐oncology
Barden M, Omuro A. Top advances of the year: Neuro‐oncology. Cancer 2023, 129: 1467-1472. PMID: 36825454, DOI: 10.1002/cncr.34711.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsBrain tumorsRecent phase 3 trialAnti-PD-1 immunotherapyCentral nervous system dysfunctionSingle-agent pembrolizumabHigh-dose chemotherapyPhase 3 trialPrimary CNS lymphomaStem cell transplantationLong-term outcomesLimited therapeutic optionsNervous system dysfunctionOngoing clinical trialsClinical trial landscapeDrug Administration approvalBRAF V600E mutationExcellent disease controlConsolidation therapyCNS lymphomaImproved survivalLeptomeningeal metastasesTherapeutic optionsCell transplantationCraniospinal irradiationPatient population
News
Copy Link
Get In Touch
Copy Link